Table 1.
Baseline clinical and laboratory data for study population categorized by carbamylated albumin tertile
| Baseline characteristic | Carbamylated albumin tertile | P-value | ||
|---|---|---|---|---|
| C-Alb values under 0.72 (n = 387) | C-Alb values 0.72 to 0.90 (n = 387) | C-Alb values over 0.90 (n = 387) | ||
| Age (years) | 65 ± 9 | 66 ± 8 | 66 ± 8 | 0.099 |
| Male | 52 | 57 | 54 | 0.364 |
| Proportion of subjects receiving atorvastatin | 46.0% (178) | 50.6% (196) | 50.9% (197) | 0.307 |
| Duration of dialysis (months) | 9.3 ± 7.1 | 8.3 ± 6.9 | 7.2 ± 6.4 | <0.001 |
| Pre-dialysis BUN (mg/dL) | 102 ± 54 | 121 ± 61 | 139 ± 65 | <0.001 |
| Post-dialysis BUN (mg/dL)* | 38 ± 19 | 51 ± 26 | 54 ± 27 | <0.001 |
| Urea reduction ratio (%)* | 64 ± 9 | 60 ± 14 | 61 ± 10 | 0.011 |
| Creatinine (mg/dL) | 6.6 ± 2.2 | 7.0 ± 2.2 | 7.0 ± 2.4 | 0.004 |
| Systolic blood pressure (mmHg) | 145 ± 22 | 146 ± 22 | 146 ± 22 | 0.850 |
| Diastolic blood pressure (mmHg) | 76 ± 11 | 76 ± 11 | 76 ± 11 | 0.934 |
| BMI (kg/m2) | 28.2 ± 4.8 | 27.2 ± 4.5 | 27.0 ± 4.9 | 0.001 |
| Alkaline phosphatase (IU/L) | 121 ± 50 | 119 ± 50 | 133 ± 80 | 0.003 |
| Troponin T (ng/mL) | 0.07 ± 0.11 | 0.08 ± 0.10 | 0.10 ± 0.12 | 0.006 |
| NT-Pro-BNP (pg/mL) | 5886 ± 9676 | 7776 ± 14697 | 10754 ± 15431 | <0.001 |
| Creatinine kinase (U/L) | 66 ± 70 | 69 ± 55 | 72 ± 51 | 0.336 |
| C-reactive protein (ng/mL) | 10.8 ± 15.1 | 9.4 ± 13.0 | 11.6 ± 22.2 | 0.202 |
| Total cholesterol (mg/dL) | 224 ± 42 | 220 ± 43 | 215 ± 42 | 0.016 |
| LDL cholesterol (mg/dL) | 124 ± 28 | 126 ± 29 | 127 ± 31 | 0.400 |
| HDL cholesterol (mg/dL) | 34 ± 12 | 36 ± 13 | 39 ± 15 | <0.001 |
| Albumin (g/dL) | 3.81 ± 0.3 | 3.84 ± 0.3 | 3.82 ± 0.3 | 0.354 |
| Hemoglobin (g/L) | 11.1 ± 1.3 | 10.9 ± 1.3 | 10.7 ± 1.3 | 0.004 |
| Transferrin saturation (%) | 22.9 ± 12.1 | 22.6 ± 10.9 | 21.1 ± 11.1 | 0.054 |
| Calcium (mmol/L) | 2.33 ± 0.21 | 2.30 ± 0.20 | 2.29 ± 0.24 | 0.007 |
| Ferritin (pmol/L) | 537 ± 461 | 480 ± 429 | 450 ± 384 | 0.016 |
| Potassium (mmol/L) | 5.1 ± 0.9 | 5.1 ± 0.8 | 5.3 ± 0.8 | 0.007 |
| Phosphorus (mg/dL) | 5.6 ± 1.4 | 6.1 ± 1.6 | 6.4 ± 1.7 | <0.001 |
| Platelets (103/μL) | 256 ± 76 | 254 ± 76 | 261 ± 87 | 0.490 |
| Intact parathyroid hormone (ng/L) | 93 ± 122 | 100 ± 101 | 115 ± 139 | 0.041 |
| White blood cells (103/μL) | 8.0 ± 2.3 | 8.0 ± 2.3 | 8.4 ± 2.7 | 0.060 |
| Aspartate aminotransferase (IU/L) | 14 ± 6 | 14 ± 16 | 14 ± 7 | 0.890 |
| HbA1c (%) | 6.7 ± 1.2 | 6.7 ± 1.3 | 6.7 ± 1.3 | 0.847 |
| Duration of diabetes (years) | 17 ± 9 | 18 ± 9 | 19 ± 9 | 0.162 |
| Prevalence of comorbid conditions present at baseline | ||||
| Congestive heart failure | 32.8% (127) | 31.0% (120) | 35.6% (166) | 0.001 |
| Atrial fibrillation | 17.1% (66) | 16.0% (62) | 22.5% (87) | 0.046 |
| Hypertension | 84.8% (328) | 90.4% (350) | 90.7% (351) | 0.013 |
| Coronary artery disease | 27.7% (107) | 28.7% (111) | 33.3% (129) | 0.184 |
| Peripheral vascular disease | 45.7% (177) | 44.4% (172) | 44.7% (173) | 0.930 |
| Cerebrovascular accident | 18.9% (73) | 18.3% (71) | 16.0% (62) | 0.545 |
| Blood pressure medication | ||||
| ACE inhibitors | 45.2% (175) | 48.1% (186) | 49.9% (193) | 0.426 |
| Calcium antagonists | 35.1% (136) | 41.6% (161) | 45.5% (176) | 0.013 |
| Diuretics | 78.8% (305) | 78.0% (302) | 82.9% (321) | 0.186 |
| Beta blockers | 38.5% (149) | 39.5% (153) | 36.2% (140) | 0.615 |
Data are expressed as mean ± SD for continuous variables and percentages (%) with number of cases for categorical data. Analysis of variance was used to test for differences between groups for continuous variables, Chi square testing was used to test for significant differences between proportions for categorical variables.
*
Post-dialysis urea and urea reduction ratio values were available for 471 of the 1,1161 subjects.